Probiotix Health PLC PBX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX9.75
- Day Range
- GBX8.60–8.60
- 52-Week Range
- —–—
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 158.17M
- Market Cap
- —
- Volume/Avg
- 1,331 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.89
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 12
- Website
- https://www.probiotixhealth.com
Valuation
|
Metric
|
PBX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 20.98 |
Price/Sales | 4.89 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PBX
|
|---|---|
Quick Ratio | 5.07 |
Current Ratio | 5.07 |
Interest Coverage | — |
Quick Ratio
PBX
Profitability
|
Metric
|
PBX
|
|---|---|
Return on Assets (Normalized) | −10.65% |
Return on Equity (Normalized) | −21.05% |
Return on Invested Capital (Normalized) | −13.65% |
Return on Assets
PBX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!rX^R< | LOCK|@yW>B | $128B | |||
| Moderna Inc
MRNA
| LOCK|fSkrWk | LOCK|?>^ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$F?^nV | LOCK|!M$ls | $76B | |||
| argenx SE ADR
ARGX
| LOCK|q@Y?<< | LOCK|Kf | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@h%Y<%@ | LOCK|ydj | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|jLgHv! | LOCK|Dw#<R | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|hHclr$p$ | LOCK|rz#zF | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|dbshq< | LOCK|ByM | $24B | |||
| Incyte Corp
INCY
| LOCK|cVf?%!V | LOCK|d@ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|P@bFqw | LOCK|Z< | $15B |
United States